MarketCap
Facebook
X
Telegram
Allena Pharmaceuticals ROA Ratio | ALNA
Annual ROA Ratio Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -29.82 | -26.35 | -138.79 | -54.65 | -22.49 | -49.53 | -20.35 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.35 | -138.79 | -48.85 |
Quarterly ROA Ratio Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -131.53 | -131.53 | -160.46 | -159.24 | -133.63 | -130.16 | -126.34 | -104.17 | -107.46 | -114.42 | -120.38 | -117.46 | -106.25 | -87.68 | -69.56 | -59.32 | -47.49 | -39.69 | -39.61 | -33.63 | -30.52 | -36.15 | -35.67 | -5.89 | -12.57 | -12.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.89 | -160.46 | -82.82 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Supernus Pharmaceuticals
SUPN
|
-2.66 | $ 26.14 | -2.24 % | $ 1.48 B |  USA |
 |
Galapagos NV
GLPG
|
9.42 | - | - | $ 1.83 B |  Belgium |
 |
Savara
SVRA
|
-46.89 | $ 4.82 | 9.93 % | $ 1.07 B | USA |
 |
Viking Therapeutics
VKTX
|
-50.25 | $ 26.86 | 4.15 % | $ 3.03 B | USA |
 |
Teligent, Inc.
TLGT
|
-12.14 | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-35.6 | - | - | $ 2.91 B | USA |
 |
TG Therapeutics
TGTX
|
42.06 | $ 59.78 | 3.1 % | $ 8.63 B | USA |
 |
Aphria Inc.
APHA
|
-3.39 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-9.61 | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
-42.41 | - | -6.00 % | $ 238 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-32.01 | $ 3.37 | 4.66 % | $ 568 M |  Singapore |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
-47.82 | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
78.84 | - | 0.38 % | $ 12.9 M |  Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
-252799694827.9 | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
-145.12 | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-28.6 | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
-39.43 | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
-15.93 | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-0.5 | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
-6.19 | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
-66.94 | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
1.23 | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
14.88 | $ 928.5 | 3.77 % | $ 56.9 B |  Niderland |
 |
XBiotech
XBIT
|
-30.34 | $ 1.88 | 0.53 % | $ 57.3 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
-18.6 | - | -2.54 % | $ 57.2 M | USA |
 |
Xencor
XNCR
|
-10.5 | $ 36.19 | 6.28 % | $ 2.69 B | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
-75.26 | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
-76.99 | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
-21.46 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
-16722.69 | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
-32.05 | $ 1.87 | 0.31 % | $ 3.18 M | USA |
 |
Translate Bio, Inc.
TBIO
|
-6.04 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-19.73 | - | - | $ 1.94 B | Canada |
 |
Exicure
XCUR
|
-35.23 | $ 0.91 | 2.77 % | $ 5.73 M | USA |
 |
Urovant Sciences Ltd.
UROV
|
-231.84 | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-13.39 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
-49.24 | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
-32.16 | - | -4.97 % | $ 664 M | USA |
|
Yunhong International
ZGYH
|
-1.14 | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
-54.65 | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-54.63 | $ 39.02 | 3.56 % | $ 3.09 B | Canada |
 |
Leap Therapeutics
LPTX
|
3.06 | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
-54.44 | $ 29.63 | 3.1 % | $ 1.53 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-119.54 | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
23.54 | $ 12.73 | -3.67 % | $ 3.03 B | USA |
 |
Cortexyme
CRTX
|
-89.8 | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
0.94 | $ 3.6 | -9.22 % | $ 789 M | Britain |
 |
Daré Bioscience
DARE
|
-41.26 | $ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
-42.74 | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-313.34 | $ 15.15 | 3.41 % | $ 205 M | USA |